Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
169.54 USD
0.98%
Market Closed
Updated:
Apr 24, 2024
Abbvie Inc
Capital Expenditures
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Capital Expenditures Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$777m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$585m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-12%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$258.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$926.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-19%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Capital Expenditures
-$161m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-176%
|
CAGR 10-Years
-23%
|
See Also
What is Abbvie Inc's Capital Expenditures?
Capital Expenditures
-777m
USD
-777m
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Capital Expenditures amounts to -777m USD.
What is Abbvie Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-5%
-5%
Over the last year, the Capital Expenditures growth was -12%. The average annual Capital Expenditures growth rates for Abbvie Inc have been 1% over the past three years , -4% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
